Cytokine serum levels in patients with cervical intraepithelial neoplasia grade II-III treated with intralesional interferon-α 2b

Tumori

Volumn 97, Issue 5, 2011, Pages 578-584

  Misson, Daniela Ribeiro ^a   Abdalla, Douglas Reis ^b   Borges, Ariana Melo ^b   Shimba, Denis Sakamoto ^e   Adad, Sheila Jorge ^c   Michelin, Márcia Antoniazi ^d   Candido Murta, Eddie Fernando ^e  

^a Gynecology and Obstetrics   (Italy)

^b General Pathology   (Italy)

^c Discipline of Special Pathology   (Italy)

^d Oncology Research Institute (IPON)   (Italy)

^e Federal University of the Triangulo Mineiro UFTM   (Brazil)

Author keywords

Cervical intraepithelial neoplasia II III; Cytokines; Interferon 2b; Interleukin 12

Indexed keywords

BLAUFERON B; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; SMOKING; UTERINE CERVIX CARCINOMA IN SITU; UTERUS BIOPSY;

EID: 83055170763     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700507     Document Type: Article

References (45)

1. Kumar V, Abbas, AK, Fausto N, Mitchell RN: Robbins Basic Pathology (8th edn), pp 718-721, Saunders Elsevier, 2007.
2. World Health Organization: Human papillomavirus infection and cervical cancer, 2009. Available at http://www.who.int/vaccine-research/diseases/hpv/en/
3. Arbyn M, Autier P, Ferlay J: Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann Oncol, 18: 1423-1425, 2007. (Pubitemid 47305020)
4. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von Karsa L: European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition - Summary Document. Ann Oncol, 21: 448- 458, 2010.
5. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: American Society for Colposcopy and Cervical Pathology-Sponsored Consensus Conference. 2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol, 197: 340-345, 2007. (Pubitemid 47464166)
6. Jakobsson M, Gissler M, Sainio S, Paavonen J, Tapper AM: Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol, 109: 309-313, 2007. (Pubitemid 46197421)
7. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E: Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet, 367: 489-498, 2006. (Pubitemid 43208905)
8. Ferrantini M, Capone I, Belardelli F: Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie, 89(6-7): 884-894, 2007.
9. Haller O, Kochs G, Weber F: The interferon response circuit: induction and suppression by pathogenic viruses. Virology, 344(1):119-130, 2006. (Pubitemid 41814456)
10. Choo YC, Seto WH, Hsu C, Tany YH, Ma HK, Ng MH: Cervical intraepithelial neoplasia treated by perilesional injection of interferon. Br J Obstet Gynaecol, 93: 372-379, 1986. (Pubitemid 16106875)
11. Dunhan AM, McCartney JC, McCance DJ, Taylor RW: Effect of perilesional injection of α-interferon on cervical intraepithelial neoplasia and associated human papillomavirus infection. J R Soc Med, 83: 490-492, 1990. (Pubitemid 20248505)
12. Stellato G: Intralesional recombinant alpha 2B interferon in the treatment of human papillomavirus-associated cervical intraepithelial neoplasia. Sex Transm Dis, 19: 124-126, 1992.
13. Ramos MC, Mardegan MC, Peghini BC, Adad SJ, Michelin MA, Murta EFC: Expression of cytokines in cervical stroma in patients with high-grade cervical intraepithelial neoplasia after treatment with intralesional interferon α-2b. Eur. J Gynaec Oncol 31(5): 522-529, 2010.
14. Bell MC, Edwards RP, Partridge EE, Kuykendall K, Conner W, Gore H, Turbat-Herrara E, Crowley-Nowick PAC: CD8+ T lymphocytes are recruited to neoplastic cervix. J Clin Imunnol, 15(3): 130-136, 1995.
15. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin, 55: 74-108, 2005. (Pubitemid 40372904)
16. Schoell WM, Janicek MF, Mirhashemi R: Epidemiology and biology of cervical cancer. Semin Surg Oncol, 16(3): 203-211, 1999. (Pubitemid 29177578)
17. Castellsaqué X, Muñoz N: Chapter 3: cofactors in human papillomavirus carcinogenesis - role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr, 31: 20-28, 2003.
18. Ault KA: Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol, suppl. 40470: 1-5, 2006.
19. Mougin C, Dalstein V, Pretet JL, Gay C, Schaal JP, Riethmuller D: Epidemiology of cervical papillomavirus infections. Recent knowledge. Presse Med, 30(20): 1017-1023, 2001. (Pubitemid 32547593)
20. Shipitsyna E, Zolotoverkhaya E, Kuevda D, Nasonova V, Romanyuk T, Khachaturyan A, Orlova O, Abashova E, Kostyuchek I, Shipulina O, Anttila A, Savicheva A: Prevalence of high-risk human papillomavirus types and cervical squamous intraepithelial lesions in women over 30 years of age in St. Petersburg, Russia. Cancer Epidemiology, 2010. doi:10.1016/ j.canep.2010.08.010
21. Runowicz CD, Lymberis S, Tobias D: Cervical neoplasia and cigarette smoking: are they linked? Medscape Womens Health, 2(3): 2, 1997.
22. Tollerud DJ, Clark JW, Brown LM, Neuland CY, Mann DL, Pankiw-Trost LK, Blattner WA, Hoover RN: Association of cigarette smoking with decreased numbers of circulating natural killer cells. Am Rev Respir Dis, 139(1): 194, 1989.
23. Mehta H, Nazzal K, Sadikot RT: Cigarette smoking and innate immunity. Inflamm Res, 57: 497, 2008.
24. Stellato G: Intralesional recombinant alpha 2B interferon in the treatment of human papillomavirus-associated cervical intraepithelial neoplasia. Sex Transm Dis, 19: 124-126, 1992.
25. Murta EFC, Tavares Murta BM: Successful pregnancy after vaginal cancer treated with interferon. Tumori, 90(2): 247-248, 2004.
26. Micheletti L, Barbero M, Preti M, Zanotto Valentino MC, Nicolaci P, Corbella L, Borgno G: Intra-lesion administration of beta-interferon in the treatment of CIN associated with HPV infection. Minerva Ginecol 44(6): 329-334, 1992.
27. Penna C, Fallani MG, Gordigiani R, Sonni L, Taddei GL, Marchionni M: Intralesional beta-interferon treatment of cervical intraepithelial neoplasia associated with human papillomavirus infection. Tumori, 80(2): 146-150, 1994. (Pubitemid 24210747)
28. Cinel A, Wittenberg L, Minucci D: Beta-interferon topical treatment in low and high risk cervical lesions. Clin Exp Obstet Gynecol, 18(2): 91-97, 1991.
29. Sikorski M, Zrubek H: Long-term follow-up of patients treated with recombinant human interferon gamma for cervical intraepithelial neoplasia. Int J Gynecol Obstet, 82: 179-185, 2003. (Pubitemid 36842843)
30. Sikorski M, Bobek M, Zrubek H, Marcinkiewicz J: Dynamics of selected MHC class I and II molecule expression in the course of HPV positive CIN treatment with the use of human recombinant IFN-&γαμμα;. Acta Obstet Gynecol Scand, 83(2): 299-307, 2004. (Pubitemid 38338872)
31. Ressing ME, Van Driel WJ, Celis E, Sette A, Brandt MP, Hartman M, Anholts JD, Schreuder GM, Ter Harmsel WB, Fleuren GJ, Trimbos BJ, Kast WM, Melief CJ: Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res, 56(3): 582-588, 1996.
32. Tsukui T, Hildesheim A, Schiffman MH, Lucci J, Contois D, Lawler P, Rush BB, Lorincz AT, Corrigan A, Burk RD, Qu W, Marshall MA, Mann D, Carrington M, Clerici M, Shearer GM, Carbone DP, Scott DR, Houghten RA, Berzofsky JA: Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res, 56(17): 3967-3974, 1996. (Pubitemid 26284746)
33. Gaiotti D, Chung J, Iglesias M, Nees M, Baker PD, Evans CH, Woodworth CD: Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol Carcinog, 27(2): 97-109, 2000. (Pubitemid 30090591)
34. De Gruijl TD, Bontkes HJ, Van Den Muysenberg AJ, Van Oostveen JW, Stukart MJ, Verheijen RH, van der Vange N, Snijders PJ, Meijer CJ, Walboomers JM, Scheper RJ: Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer, 35(3): 490-497, 1999. (Pubitemid 29157871)
35. Peters JH, Gieseler R, Thiele B, Steinbach F: Dendritic cells: from oncogenetic orphans to myelomonocytic descendants. Immunol Today, 17(6): 273-278, 1996. (Pubitemid 26183491)
36. Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, Venzon DJ, Shearer GM, De Palo G, Clerici E: Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst, 89(3): 245-250, 1997. (Pubitemid 27073762)
37. Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ, Helmerhorst TJ: A shift to a peripheral Th2- type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol, 58(10): 1096-1100, 2005. (Pubitemid 41416062)
38. El-Sherif AM, Seth R, Tighe PJ, Jenkins D: Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer. J Pathol, 195(2): 179-185, 2001. (Pubitemid 32899026)
39. Tavares-Murta BM, De Resende AD, Cunha FQ, Murta EFC: Local profile of cytokines and nitric oxide in patients with bacterial vaginosis and cervical intraepithelial neoplasia. Eur J Obstet Gynecol Reprod Biol, 138(1): 93-99, 2008. (Pubitemid 351608111)
40. Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, Hsieh CY: Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol, 82: 49-56, 2001.
41. Fujimoto J, Sakaguchi H, Aoki I, Tamaya T: Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res, 60: 2632-2635, 2000. (Pubitemid 30318237)
42. Mardegan MC, Ramos MC, Adad SJ, Michelin MA, Shimba D, Murta EFC: Immunological evaluation of vaginal secretion in patients with high-grade cervical intra-epithelial neoplasia treated with intralesional interferon &αλπηα;-2b. Eur J Gynaecol Oncol, 32: 297-302, 2011.
43. Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, Honjo T: IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol, 186(5): 2772-2779, 2011.
44. Santini SM, Lapenta C, Donati S, Spadaro F, Belardelli F, Ferrantini M: Interferon-a-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 Responses: role of IL-23 and IL-12. PLoS ONE 6(2): e17364, 2011. doi:10.1371/journal.pone.0017364
45. Nagano H: Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology, 78 (Suppl. 1): 142-147, 2010.